Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

(2014) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?

(2014) Elizabeth V Arkema et al.   ANNALS OF THE RHEUMATIC DISEASES

Beyond Tumor Necrosis Factor Inhibition: The Expanding Pipeline of Biologic Therapies for Inflammatory Diseases and Their Associated Infectious Sequelae

(2014) S. A. Novosad et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study

(2014) Yoshiya Tanaka et al.   Modern Rheumatology

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

(2014) Eun Bong Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human genetics of tuberculosis: a long and winding road

(2014) L. Abel et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis

(2014) Kevin L. Winthrop et al.   Arthritis & Rheumatology

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

(2013) Joel Kremer et al.   ANNALS OF INTERNAL MEDICINE

Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study*

(2013) Iain B McInnes et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study

(2013) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM

Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy

(2013) Kevin L. Winthrop et al.   Nature Reviews Rheumatology

You can't always get what you want, but if you try sometimes (with two tests—TST and IGRA—for tuberculosis) you get what you need: Figure 1

(2012) Kevin L Winthrop et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

(2012) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Mycobacterial diseases and antitumour necrosis factor therapy in USA

(2012) KL Winthrop et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of Tuberculosis Reactivation With Tofacitinib (CP-690550)

(2012) Mamoudou Maiga et al.   JOURNAL OF INFECTIOUS DISEASES

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Infections and Biologic Therapy in Rheumatoid Arthritis

(2012) Kevin L. Winthrop   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials

(2012) Elizabeth C. Hsia et al.   ARTHRITIS CARE & RESEARCH

Let the fog be lifted: screening for hepatitis B virus before biological therapy

(2011) K. L. Winthrop et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register

(2011) J. B. Galloway et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

(2011) A. Strangfeld et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

(2011) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

(2011) Roy Fleischmann et al.   ARTHRITIS AND RHEUMATISM

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2011) Yoshiya Tanaka et al.   ARTHRITIS CARE & RESEARCH

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry

(2010) D. Salmon-Ceron et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

(2010) Debra M Meyer et al.   Journal of Inflammation-London

The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy

(2010) Kevin L. Winthrop et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry

(2009) J D Greenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

(2009) W. G. Dixon et al.   ANNALS OF THE RHEUMATIC DISEASES

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

(2009) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry

(2009) F. Tubach et al.   ARTHRITIS AND RHEUMATISM

Herpes Zoster Risk Factors in a National Cohort of Veterans with Rheumatoid Arthritis

(2009) Jay R. McDonald et al.   CLINICAL INFECTIOUS DISEASES

Preventing and treating biologic-associated opportunistic infections

(2009) Kevin L. Winthrop et al.   Nature Reviews Rheumatology

Latent Infection and Tuberculosis Disease in Rheumatoid Arthritis Patients

(2009) Eduardo Acevedo-Vásquez et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade

(2008) Robert S. Wallis   ARTHRITIS AND RHEUMATISM

Mycobacterial and Other Serious Infections in Patients Receiving Anti–Tumor Necrosis Factor and Other Newly Approved Biologic Therapies: Case Finding through the Emerging Infections Network

(2008) Kevin L. Winthrop et al.   CLINICAL INFECTIOUS DISEASES